<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00130884</url>
  </required_header>
  <id_info>
    <org_study_id>3001081</org_study_id>
    <nct_id>NCT00130884</nct_id>
  </id_info>
  <brief_title>Peroral Levosimendan in Chronic Heart Failure</brief_title>
  <official_title>Effects of Peroral Levosimendan in the Prevention of Further Hospitalisations in Patients With Chronic Heart Failure. A Randomised, Phase II, Double-Blind, Placebo-Controlled, Multi-Centre, Parallel-Group Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orion Corporation, Orion Pharma</source>
  <brief_summary>
    <textblock>
      The study will investigate the efficacy of oral levosimendan in patients with chronic New
      York Heart Association (NYHA) IIIb-IV heart failure (HF) using a composite end-point
      evaluating patient symptoms, morbidity and mortality. The patients are on treatment for at
      least 6 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients are randomised to 3 groups; higher or lower levosimendan dose group or placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date>March 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite endpoint measuring symptoms, morbidity, mortality</measure>
  </primary_outcome>
  <enrollment>300</enrollment>
  <condition>Chronic Heart Failure</condition>
  <condition>Heart Diseases</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levosimendan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed chronic heart failure

          -  Severe symptoms (NYHA IIIb-IV)

          -  Optimal on-going oral treatment for HF

          -  Left ventricular ejection fraction less than or equal to 30%

        Exclusion Criteria:

          -  Severe obstruction of ventricular outflow tracts

          -  Acute myocardial infarction within 30 days before screening

          -  Cardiac surgery or coronary angioplasty within 30 days before screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markku S Nieminen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital, Finland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>February 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2005</study_first_submitted>
  <study_first_submitted_qc>August 15, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2005</study_first_posted>
  <last_update_submitted>February 19, 2007</last_update_submitted>
  <last_update_submitted_qc>February 19, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2007</last_update_posted>
  <keyword>levosimendan</keyword>
  <keyword>chronic heart failure</keyword>
  <keyword>oral administration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simendan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

